New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Lexaria Bioscience Corp. (LEXX) vs TScan Therapeutics, Inc. (TCRX)

Lexaria Bioscience Corp. and TScan Therapeutics, Inc. are both Biotechnology companies. Lexaria Bioscience Corp. and TScan Therapeutics, Inc. are of similar size ($9.5M and $9.4M). Lexaria Bioscience Corp. grew revenue faster over the last twelve months: 52.0% against −38.4%. Lexaria Bioscience Corp. has the higher net margin (−1,686.1% vs −2,219.2%) and the lower return on invested capital (−662.6% vs 0.00%). Across the 18 metrics below, Lexaria Bioscience Corp. leads on 9 and TScan Therapeutics, Inc. on 9.

Valuation

Metric LEXX TCRX Biotechnology median
P/E n/m n/m 8.49
P/S 12.30 3.76 8.56
P/B 1.53 0.51 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m 0.18 0.69
EV/Sales 5.63 (3.96) 8.00
Earnings yield (129.52%) (589.60%) (35.81%)
Free cash flow yield (112.89%) (572.40%) (25.41%)

Profitability

Metric LEXX TCRX Biotechnology median
Gross margin 99.62% 100.00% 70.18%
Operating margin (1,683.06%) (2,246.84%) 0.00%
Net margin (1,686.05%) (2,219.19%) 0.00%
Free cash flow margin (1,494.56%) (2,152.72%) 0.00%
Return on equity (162.60%) (126.45%) (51.58%)
Return on assets (134.20%) (57.03%) (45.91%)
Return on invested capital (662.56%) 0.00% 0.00%

Growth

Metric LEXX TCRX Biotechnology median
Revenue growth (TTM) 52.04% (38.43%) 7.20%
EPS growth (last fiscal year) (40.43%) 12.28% 29.04%
Revenue growth, 5-year CAGR 17.53% 56.92% 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric LEXX TCRX Biotechnology median
Debt to equity 0.00 0.87 0.00
Current ratio 10.60 2.03 4.79
Net debt to EBITDA 0.17 0.90 1.01

Dividend

Metric LEXX TCRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LEXX TCRX Biotechnology median
Market cap 9.46m 9.42m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack